David Cohen

机构：AstraZeneca (Netherlands), AstraZeneca (Singapore), AstraZeneca (Japan), AstraZeneca (Spain), New York University · ORCID：0000-0001-7318-8567

发表论文 276 篇 · 总被引 8971 次 · h-index 51

代表论文

• Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study (2023 · The Lancet · 被引 150)
• Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme (2024 · European Respiratory Journal · 被引 60)
• Mendelian Randomization Analysis of Genetic Proxies of Thiazide Diuretics and the Reduction of Kidney Stone Risk (2023 · JAMA Network Open · 被引 41)
• Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial (2024 · British Journal of Clinical Pharmacology · 被引 16)
• Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study (2024 · Journal of Asthma and Allergy · 被引 15)
• Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia (2024 · Respiratory Medicine · 被引 14)